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Abstract
Background: Previous studies have revealed the significance of Helicobacter pylori (H. pylori) infection as a risk
factor of gastric cancer. Cytotoxin-associated gene A (cagA) positivity has been demonstrated to determine the
clinical outcome of H. pylori infection in the presence of SHP-2 (src homology 2 domain-containing protein
tyrosine phosphatase-2). This study aimed to examine the formerly reported association of G/A PTPN11 (protein-
tyrosine phosphatase, nonreceptor-type 11) polymorphism (rs2301756) with gastric atrophy, as well as the
association with gastric cancer in a Japanese population using a large sample size.
Methods: Study subjects were 583 histologically diagnosed patients with gastric cancer (429 males and 154
females) and age- and sex-frequency-matched 1,636 non-cancer outpatients (1,203 males and 433 females), who
visited Aichi Cancer Center Hospital between 2001–2005. Serum anti-H. pylori IgG antibody and pepsinogens
were measured to evaluate H. pylori infection and gastric atrophy, respectively. Odds ratios (ORs) and 95%
confidence intervals (CIs) were calculated by a logistic model.
Results: Among H. pylori seropositive non-cancer outpatients, the age- and sex-adjusted OR of gastric atrophy
was 0.82 (95% CI 0.62–1.10, P = 0.194) for G/A, 0.84 (95% CI 0.39–1.81, P = 0.650) for A/A, and 0.83 (95% CI 0.62–
1.09, P = 0.182) for G/A+A/A, relative to G/G genotype, and that of severe gastric atrophy was 0.70 (95% CI 0.47–
1.04, P = 0.079), 0.56 (95% CI 0.17–1.91, P = 0.356), and 0.68 (95% CI 0.46–1.01, P = 0.057), respectively. Among
H. pylori infected subjects (H. pylori seropositive subjects and seronegative subjects with gastric atrophy), the
adjusted OR of severe gastric atrophy was further reduced; 0.62 (95% CI 0.42–0.90, P = 0.012) for G/A+A/A. The
distribution of the genotype in patients with gastric cancer was not significantly different from that for H. pylori
infected subjects without gastric atrophy.
Conclusion: Our study results revealed that those with the A/A genotype of PTPN11 rs2301756 polymorphism
are at lower risk of severe gastric atrophy, but are not associated with a decreased risk of gastric cancer, which
partially supported our previous finding that the polymorphism in the PTPN11 gene encoding SHP-2 was
associated with the gastric atrophy risk in H. pylori infected Japanese. The biological roles of this PTPN11
polymorphism require further investigation.
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Helicobacter pylori (H. pylori) infection is a well-established
risk factor of gastric cancer through the development of
gastric atrophy and subsequent precancerous lesions. Par-
ticularly, H. pylori strains with the cytotoxin-associated
gene A (cagA) are in a strong association with increased
gastric adenocarcinoma risk [1]. Severe gastric atrophy
and corpus-predominant gastritis along with intestinal
metaplasia are well established as predominant predispo-
sitions to gastric cancer [2]. Host proinflammatory genetic
factors in combination with bacterial virulence factors
such as CagA have been reported to determine the severity
of gastric damage and the eventual clinical outcome of H.
pylori infection [3,4]. The risk of gastric cancer is multi-
plied several fold if the host harbors both of these factors
[5,6]. In East Asian populations, great majority of H. pylori
are cagA-positive strains. CagA is divided into two major
subtypes, East Asian type and Western type [7]. The grade
of gastric atrophy and gastric cancer risk is higher in
patients with East Asian cagA-positive strains than in those
with cagA-negative or Western cagA-positive strains [8].
CagA protein is translocated from attached H. pylori into
host gastric epithelial cells via a bacterial type IV secretion
apparatus, and undergoes tyrosine phosphorylation in the
host cells [9]. It induces the scattering phenotypes in gas-
tric epithelial cells, called the "hummingbird phenotype,"
which is thought to play a crucial role in the pathogenesis
of cagA-positive H. pylori infection, eventually leading to
gastric carcinoma. In this CagA-dependent morphological
transformation of gastric epithelial cells, the existence of
SHP-2 (src homology 2 domain-containing protein tyro-
sine phosphatase-2) is essential [10]. SHP-2 plays a key
role in intracellular signaling downstream of a number of
growth factors, hormones, and cytokines [11,12]. The
translocated CagA forms a physical complex with SHP-2
thereby stimulating its phosphatase activity [10]. Subse-
quent Erk (extracellular signal-regulated kinase) activity
also contributes to the CagA-induced "hummingbird phe-
notype" [13]. Thus, CagA/SHP-2 complex formation may
induce abnormal proliferation, movement of gastric epi-
thelial cells and cellular changes that might conclusively
lead to gastric atrophy and gastric carcinoma.
Since SHP-2 closely interacts with the CagA protein, it is
natural to speculate that functional polymorphisms in the
PTPN11 (protein-tyrosine phosphatase, nonreceptor-type 11)
gene encoding SHP-2 may ultimately influence the degree
of gastric atrophy and transformation to gastric cancer in
infected subjects. There are 9 single nucleotide polymor-
phisms (SNPs) at minor allele frequency > 0.05 in
PTPN11 gene in Japanese on HapMap, all of which are
located in non-coding regions, and most of them are in
absolute linkage disequilibrium (LD) (D' = 1 and r2 = 1)
or complete linkage disequilibrium (D' = 1 and r2 < 1) to
each other. Five of the 9 SNPs are shown to be in complete
LD and 3 of them are shown to be in absolute LD or nearly
absolute LD (D' = 1 and r2 > 0.9) in Caucasians as shown
in Figure 1, based on HapMap homepage http://
www.hapmap.org. Our recent report revealed that one
PTPN11 G/A SNP at intron 3 (rs2301756) was in com-
plete LD to another PTPN11 G/A SNP at intron 10
(rs12229892) [14]. In this study, the G/A SNP at intron 3
(rs2301756), one of the 3 SNPs in absolute LD was
selected as a representative of these linked SNPs.
In H. pylori related gastric cancer, the process leading to
disease has three steps; H. pylori infection, gastric atrophy
development and carcinogenesis. At each step, genetic
traits and their interactions with lifestyle may influence
the process [15]. For genetic traits, significant associations
of interleukin (IL) -1B C-31T and C-511T polymorphisms
[16,17], tumor necrosis factor (TNF)-α C-857T and T-
1031C polymorphisms [18], and a NAD(P)H dehydroge-
nase, quinone 1 (NQO1) C609T polymorphism [19] with
H. pylori infection, and associations of a G/A polymor-
phism at intron 2 of Grb2-associated binder 1 (Gab1) [20],
interleukin (IL) 2 T-330G, and IL-13 C-1111T [21] with
gastric atrophy have been reported to date. Variable
number of tandem repeats (VNTR) polymorphisms of
mucin 1 (MUC1) have also been shown to influence H.
pylori infection [22,23]. Although there are several studies
to demonstrate the polymorphisms significantly associ-
ated with the risk of gastric cancer, only a few studies eval-
uated the risk for the step from gastric atrophy to gastric
cancer [15].
In our previous studies among Japanese and Japanese Bra-
zilians, the AA genotype in intron 3 was shown to reduce
the risk of gastric atrophy development [24,25]. Recently,
another PTPN11 SNP (rs11066322 at intron 10 in com-
plete linkage disequilibrium to rs2301756) was found to
be significantly associated with serum apoB levels in a
British population [26], supporting the hypothesis that
this PTPN11 polymorphism is functional. This study
aimed to confirm the formerly reported association
between the PTPN11 polymorphism (rs2301756) and
gastric atrophy measured with serum pepsinogens in a
large number of Japanese subjects, as well as to examine
the association with gastric cancer risk.
Methods
Subjects
Subjects were participants of HERPACC (Hospital-based
Epidemiologic Research Program at Aichi Cancer Center)
study, in which first-visit outpatients were consecutively
invited to provide lifestyle data and blood sample after
obtaining informed consent [27]. Among the participants
who visited Aichi Cancer Center Hospital from 2001 –
2005, 583 cases diagnosed as gastric cancer and age- and
sex-frequency-matched 1,638 cancer free outpatients were
sampled as a control group, among whom two outpa-Page 2 of 8
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leaving 583 cases and 1,636 controls eligible for the anal-
yses. Informed consent was obtained from all the subjects
and the study protocol was approved by the Ethics Com-
mittees of Aichi Cancer Center and Nagoya University
Graduate School of Medicine.
Samples and diagnostic criteria
Their serum samples were immediately stored at -20°C
until analysis. Anti-H. pylori IgG antibody was measured
with an enzyme immunoassay (EIA) kit "E plate 'Eiken' H.
pylori Antibody" (Eiken Kagaku, Tokyo, Japan). According
to the instructions provided with this kit, 10.0 units or
higher was regarded as seropositive. Serum pepsinogens
(PG) were measured by chemiluminescence enzyme
immunoassay (CLEIA). Gastric mucosal atrophy was
grouped into "none" (PG I > 70 ng/ml or PG I/PG II > 3),
"mild" (PG I ≤ 70 ng/ml and PG I/PG II ≤ 3, excluding
"severe" cases), or "severe" (PG I ≤ 30 ng/ml and PG I/PG
II ≤ 2). Since serum samples of gastric cancer cases were
planned to be used for a study with higher priority, the
antibody and PGs of the cases were not measured.
Genotyping
DNA was extracted from buffy coat using the Qiagen
DNeasy mini kit (Qiagen, Hilden, Germany). The
PTPN11 G/A polymorphism (rs2301756) was genotyped
with a polymerase chain reaction with confronting two-
pair primers (PCR-CTPP) [28]. The primers were F1: GGA
TTA CAG GCA TAA GCC AC, R1: GAC CAC TAA ACT TCT
TAA ATG AGC, F2: CAT TTG TCT CTA AAG GAC TGT
GGA, and R2: CTC TGG CTC TCT CGT ACA AGA. Ampli-
fication conditions were 10 min of initial denaturation at
95°C, followed by 30 cycles of 1 min at 95°C, 1 min at
64°C, and 1 min at 72°C, then a 5-min final extension at
72°C. The amplified DNA was visualized on a 2% agarose
gel with ethidium bromide staining. The amplified DNA
was 201 bp for G/G genotype, 201 bp and 339 bp for G/A
genotype, 339 bp for A/A genotype, and 490 bp for com-
mon band [24].
Linkage disequilibrium (LD) between the 9 single nucleotide polymorphisms (SNPs) with a minor allele frequency > 0.05 in the PTPN11 gene region among Caucasians (CEU: Utah r sidents with ancestry from northern and western Europe)Figur 1
Linkage disequilibrium (LD) between the 9 single nucleotide polymorphisms (SNPs) with a minor allele fre-
quency > 0.05 in the PTPN11 gene region among Caucasians (CEU: Utah residents with ancestry from north-
ern and western Europe). LD maps are shown by two parameters, r2 and D' for Caucasians (CEU: Utah residents with 
ancestry from northern and western Europe). SNP numbers in the LD maps correspond to the rs numbers described in the 
upper right of the maps.
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The differences in proportions were examined with a
Fisher's exact test. The 95% confidence intervals (CIs) for
percentages were calculated based on binomial distribu-
tions. Logistic regression analysis was performed for esti-
mating odds ratios (ORs) and 95% CIs. Age was adjusted
as a continuous variable in the logistic model. H. pylori
infected subjects was defined as those with H. pylori sero-
positivity or with gastric atrophy, because in the great
majority of cases gastric atrophy develops after H. pylori
infections. The trends for H. pylori infection, gastric atro-
phy or gastric cancer development by sex or age categories
were compared using the χ2 test for trend. The calculations
were done using the STATA version 7 (Stata Corp, College
Station, TX).
Results
Characteristics of the subjects and allele frequency of the 
PTPN11 polymorphism
The characteristics of the subjects are summarized in Table
1. The mean age ± standard deviation was 58.7 ± 10.6 y
(range: 25–84 y) for controls and 58.8 ± 10.5 y (range:
27–80 y) for cases. Females were 26.5% in controls and
26.4% in cases. About three quarters of the controls were
infected with H. pylori, while about one third of the con-
trols had gastric atrophy. The genotype frequency of the
PTPN11 polymorphism among the controls was in
Hardy-Weinberg's equilibrium (χ2 = 0.047, P = 0.828). We
tested the trend for H. pylori infection, gastric atrophy or
gastric cancer development by sex or age categories, which
revealed significant trend for higher H. pylori infection rate
in males (P-value for trend < 0.001) and higher age cate-
gories (P < 0.001), and for higher prevalence of gastric
atrophy in higher age categories (P < 0.001).
PTPN11 polymorphism, H. pylori seropositivity, gastric 
atrophy and gastric cancer
There was no significant association between the PTPN11
polymorphism and the seropositivity, although the OR of
A/A genotype was 1.19 relative to G/G genotype (Table 2).
There were 937 H. pylori seropositive subjects, among
whom 495 (52.8%) subjects had atrophy. On the one
hand, there were 45 (6.4%) subjects with atrophy among
699 seronegative subjects. The difference in the preva-
lence was statistically significant (P < 0.001).
Table 3 shows the genotype distribution according to
seropositivity and atrophy. There were no subjects with A/
A genotype among the seronegative atrophy participants.
Accordingly, the adjusted OR of gastric atrophy among
the seronegative subjects was not calculable for the A/A
genotype; the genotype distribution was not significantly
associated with gastric atrophy by a 3 × 3 Fisher's exact test
(P = 0.196).
The age- and sex-adjusted OR of gastric atrophy among H.
pylori seropositive subjects was 0.82 (95% CI 0.62–1.10, P
= 0.194) for G/A, 0.84 (95% CI 0.39–1.81, P = 0.650) for
A/A, and 0.83 (95% CI 0.62–1.09, P = 0.182) for G/A+A/
A, compared with G/G genotype. The age- and sex-
adjusted OR of severe gastric atrophy among H. pylori
seropositive subjects was 0.70 (95% CI 0.47–1.04, P =
0.079) for G/A, 0.56 (95% CI 0.17–1.91, P = 0.356) for A/
Table 1: Characteristics of the subjects and the PTPN11 rs2301756 polymorphism.
Controls n = 1636 Cases n = 583
H. pylori (-) H. pylori (+)
GA (-) GA (+)
n 699 442 495 583
Sex
Male 479 (68.5%) 363 (82.1%) 361 (72.9%) 429 (73.6%)
Female 220 (31.5%) 79 (17.9%) 134 (27.1%) 154 (26.4%)
Age
< 30 6 (0.9%) 1 (0.2%) 1 (0.2%) 2 (0.3%)
30–39 67 (9.6%) 11 (2.5%) 3 (0.6%) 31 (5.3%)
40–49 138 (19.7%) 54 (12.2%) 31 (6.3%) 64 (11.0%)
50–59 194 (27.8%) 151 (34.2%) 141 (28.5%) 214 (36.7%)
60–69 211 (30.2%) 152 (34.4%) 221 (44.7%) 166 (28.5%)
70- 83 (11.9%) 73 (16.5%) 98 (19.8%) 106 (18.2%)
Genotype
G/G 483 (69.1%) 293 (66.3%) 350 (70.7%) 396 (67.9%)
G/A 198 (28.3%) 135 (30.5%) 131 (26.5%) 174 (29.9%)
A/A 18 (2.6%) 14 (3.2%) 14 (2.8%) 13 (2.2%)
GA(-) and GA(+) indicate without atrophy and with atrophy, respectively.Page 4 of 8
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when those without severe gastric atrophy were defined as
a reference (Table 4). When H. pylori seropositive subjects
and seronegative subjects with gastric atrophy were
regarded as H. pylori infected subjects, the age- and sex-
adjusted OR of severe gastric atrophy among the H. pylori
infected was further reduced; 0.62 (95% CI 0.42–0.90, P
= 0.012) for G/A+A/A (Table 4).
Figure 2 depicts the distributions of pepsinogen I/II ratio
according to PTPN11 rs2301756 genotype among H.
pylori infected subjects with PG I ≤ 70 ng/ml. In accord-
ance with the finding that subjects with A allele were at
significantly reduced risk of severe gastric atrophy, the fre-
quency of subjects with PG I/II ratio less than 2 was lower
in subjects with A allele than those with G/G genotype.
To investigate how this polymorphism of PTPN11 con-
tributes to the gastric carcinogenesis among the H. pylori
infected subjects, we also calculated the OR of gastric can-
cer compared with H. pylori infected subjects without gas-
tric atrophy. The age- and sex-adjusted OR of gastric
cancer was 0.97 (95% CI 0.74–1.28, P = 0.839) for G/A,
0.71 (95% CI 0.33–1.53, P = 0.381) for A/A, and 0.95
(95% CI 0.73–1.23, P = 0.689) for G/A+A/A, relative to G/
G genotype, none of which were statistically significant
(Table 5).
Discussion
This study revealed that those who harbor A allele of the
PTPN11 rs2301756 polymorphism at intron 3 had a sig-
nificantly lower risk of severe gastric atrophy. This is in
accordance with our hypothesis that gastric atrophy devel-
opment after cagA-positive H. pylori infection was rarer
among those with A/A genotype than among those with
G/G genotype [24,25], although the significant associa-
tion was observed only for severe gastric atrophy in this
study. Since the biological processes in infection, atrophy
development, and carcinogenesis are different [15], the
association of this polymorphism with only atrophic
development seemed biologically plausible.
While there was limited information on the potential
function of PTPN11 polymorphisms, biological character-
istics of SHP-2 have become increasingly understood.
SHP-2 is one of the two existing mammalian non-trans-
membrane (intracellular) protein tyrosine phosphatases
(PTPs) that contain src homology 2 (SH2) domains. Bind-
ing of tyrosine phosphorylated CagA to the SH2 domains
is supposed to induce conformational change in SHP-2
that weakens the inhibitory interaction between PTP and
N-terminal SH2 domains, eventually leading to the activa-
tion of SHP-2 phosphatase [10,29,30]. The G/A polymor-
phism in the intron 3 of PTPN11 is located 223 base pairs
upstream from exon 4, which encodes the initial part of C-
terminal SH2 domain. Although the biological role of the
present polymorphism is not yet clearified, the polymor-
phism may have some influence on the formation of
PTPN11 mRNA splicing variants, of which 8 forms have
been reported to date (SpliceMinor homepage developed
by The Genomics & Bioinformatics Group (GBG) of NCI:
http://www.tigerteamconsulting.com/SpliceMiner/). The
LD data between the PTPN11 SNPs shown in Figure 1 is
that for Caucasians, and no precise information about LD
in Japanese is available at present. There are also some
PTPN11 SNPs whose LD status is left unknown (SNP8
and SNP9 in Figure 1). The function of the PTPN11 poly-
morphism at exon 3 (rs2301756) and other PTPN11 SNPs
on the interaction between SHP-2 and CagA in Japanese
and other ethnicities requires further investigation.
Table 2: Odds ratios (ORs) and 95% confidence intervals (CIs) of PTPN11 rs2301756 polymorphism for H. pylori seropositivity.
Genotype, allele n H. pylori + H. pylori + (%) ORa 95% CI P value
G/G 1126 643 57.1 1 Reference -
G/A 464 266 57.3 1.02 0.81–1.28 0.865
A/A 46 28 60.9 1.19 0.64–2.22 0.577
G 2716 1552 57.1 1 Reference -
A 556 322 57.9 1.03 0.85–1.25 0.387
aOR for each genotype was calculated by age and sex adjusted logistic regression model, and a crude OR was calculated for each allele.
Table 3: PTPN11 rs2301756 genotype distribution according to H. pylori seropositivity and the grade of gastric atrophy.
Genotype H. pylori seronegative H. pylori seropositive
GA (-) GA (+) GA (++) GA (-) GA (+) GA (++)
G/G 447 (68.3%) 11 (64.7%) 25 (89.3%) 293 (68.4%) 223 (68.2%) 127 (75.6%)
G/A 189 (28.9%) 6 (35.3%) 3 (10.7%) 135 (28.9%) 93 (28.4%) 38 (22.6%)
A/A 18 (2.8%) 0 (0.0%) 0 (0.0%) 14 (2.7%) 11 (3.4%) 3 (1.8%)
Total 654 (100%) 17 (100%) 28 (100%) 442 (100%) 327 (100%) 168 (100%)
GA(-), GA(+) and GA(++) indicate no atrophy, mild atrophy and severe atrophy, respectively.Page 5 of 8
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genetic traits to develop gastric atrophy via signal trans-
duction from CagA, there seems to be other genetic traits
involved in this process. CagA binds several molecules;
Grb2, which transduces the signal to Ras-MAPK pathway
causing cell proliferation, c-Met hepatocyte growth factor
(HGF) receptor, which have a role of cell proliferation and
motility, ZO-1, a tight-junction protein, and Par1/Mark
kinase, which has an essential role in epithelial cell polar-
ity [31-35]. Although no studies have been conducted,
functional polymorphisms of these molecules might be
also candidates of genetic traits of gastric atrophy.
The A allele was the dominant allele of PTPN11 polymor-
phism at intron 3 among Caucasians (0.875 of 120 chro-
mosomes), but not among Japanese (0.178 of 902
chromosomes) and Chinese (0.083 of 48 choromo-
somes) [26]. This study found that the A allele frequency
was 0.170 among our Japanese control subjects, similar to
the reported allele frequency in Japanese.
The present study has several limitations. Although the H.
pylori status of the control subjects was examined with a
serology test, we did not check the CagA status. As
reported in Japan, nearly 100% of H. pylori strains possess
a functional cag pathogenicity island (cag PAI), which
encodes and produces the CagA protein [36]. A previous
study also certified that almost all strains isolated from
our Japanese subjects were East Asian cagA-positive strains
[37], indicating that H. pylori strains in our study subjects
also possesses CagA. Another limitation is related to the
diagnosis of gastric atrophy. This was done entirely on the
basis of serum pepsinogen levels and not through histo-
logical assessment, because most of the control subjects
did not undergo gastrointestinal endoscopy with biopsy.
However, the pepsinogen method is well established as a
Table 4: Genotype frequencies for PTPN11 rs2301756 polymorphism, odds ratios (ORs) and 95% confidence intervals (CIs) of gastric 
atrophy in the H. pylori seropositive subjects (a) and H.pylori infected subjects (b)
(a)
Genotype, allele n All gastric atrophy (%) ORa 95% CI P valueb Severe gastric atrophy 
(%)
ORb 95% CI P valueb
G/G 643 350 (54.4) 1 Reference - 127 (19.8) 1 Reference -
G/A 266 131 (49.2) 0.82 0.62–1.10 0.194 38 (14.3) 0.70 0.47–1.04 0.079
A/A 28 14 (50.0) 0.84 0.39–1.81 0.650 3 (10.7) 0.56 0.17–1.91 0.356
G/A+A/A 294 145 (49.3) 0.83 0.62–1.09 0.182 41 (13.9) 0.68 0.46–1.01 0.057
G 1552 831 (53.5) 1 Reference - 292 (18.8) 1 Reference -
A 322 159 (49.4) 0.85 0.66–1.08 0.097 44 (13.7) 0.67 0.45–0.96 0.015
(b)
Genotype, allele n All gastric atrophy (%) ORa 95% CI P valueb Severe gastric atrophy 
(%)
ORa 95% CI P valueb
G/G 677 383 (56.6) 1 Reference - 151 (22.3) 1 Reference -
G/A 274 139 (50.7) 0.80 0.60–1.06 0.123 41 (15.0) 0.63 0.43–0.93 0.019
A/A 28 14 (50.0) 0.77 0.36–1.67 0.512 3 (10.7) 0.49 0.14–1.67 0.254
G/A+A/A 302 153 (50.7) 0.80 0.60–1.05 0.106 44 (14.6) 0.62 0.42–0.90 0.012
G 1628 905 (55.6) 1 Reference - 343 (21.1) 1 Reference -
A 330 167 (50.6) 0.82 0.64–1.05 0.102 47 (14.2) 0.62 0.44–0.87 0.005
aOR for each genotype was calculated by age and sex adjusted logistic regression model, and a crude OR was calculated for each allele.
bP values less than 0.05 are shown in Italics.
Distributions of pepsinogen (PG) I/II ratio according to PTPN11 rs2301756 ge type among H. pylori infected sub-jects with a PG I l vel f ≤ 70 ng/mlFigure 2
Distributions of pepsinogen (PG) I/II ratio according 
to PTPN11 rs2301756 genotype among H. pylori 
infected subjects with a PG I level of ≤ 70 ng/ml.
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criterion for gastric atrophy is PG I ≤ 70 ng/ml and PG I/II
ratio of ≤ 3.0, and that for severe gastric atrophy is PG I ≤
30 ng/ml and PG I/II ratio of ≤ 2.0, both of which are sup-
posed to be reliable because they are widely used in prac-
tice in Japan [41,42]. Concerning the gastric cancer cases
the H. pylori seropositivity and pepsinogen levels were not
examined, but most of the gastric cancer cases seemed to
be H. pylori positive cases with gastric atrophy [43,44].
Considering that intestinal type of gastric cancer, the pre-
dominant type of gastric cancer in Japan, arises from gas-
tric atrophy caused by H. pylori infection, and diffuse type
gastric cancer occurs regardless of gastric atrophy [45], it
would seem intriguing to perform the subgroup analysis
according to these two histological types. This analysis
might unveil the association of this PTPN11 polymor-
phism with the steps of gastric carcinogenesis more
clearly. However, we could not perform this analysis
because of the unavailability of the histological data. In
addition, there might be several factors, including genetic,
that prime the individual stomach for H. pylori coloniza-
tion, which might modulate the effect of this PTPN11 pol-
ymorphism [22,23]. Further investigations with these
factors taken into consideration are also expected.
Conclusion
This study revealed that rs2301756 in the PTPN11 gene
encoding SHP-2 increased the risk of severe gastric atro-
phy in H. pylori infected subjects in Japan. Although the
significant association was limited only to severe gastric
atrophy, this study partially supported the roles of this
PTPN11 polymorphism in the gastric atrophy develop-
ment. Elucidation of the function of this polymorphism
will help us understand the pathogenesis of H. pylori-
induced gastric cancer, which will lead to more effective
means for the personalized prevention of gastric atrophy
and subsequent gastric cancer in the near future.
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